NCT05267951 Closed-loop Spinal Stimulation for Restoration of Upper Extremity Function After Spinal Cord Injury
| NCT ID | NCT05267951 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Washington |
| Condition | Spinal Cord Injuries |
| Study Type | INTERVENTIONAL |
| Enrollment | 9 participants |
| Start Date | 2022-10-12 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 9 participants in total. It began in 2022-10-12 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to assess the efficacy of non-invasive (transcutaneous) closed-loop electrical spinal cord stimulation for recovery of upper limb function (Aim 1) and spasticity (Aim 2) following spinal cord injury.
Eligibility Criteria
Inclusion Criteria: 1. has cervical (C8 or higher), incomplete (American Spinal Cord Injury Impairment Scale - C or D) traumatic spinal cord injury, minimum 1-year post-injury 2. has difficulty with hand functions in activities of daily living (e.g., dressing, grooming, feeding) 3. stable medical condition without cardiopulmonary disease or autonomic dysreflexia that would contraindicate participation in upper extremity rehabilitation or testing activities 4. capable of performing simple cued motor tasks 5. has ability to attend intervention/functional task training and assessment sessions 3 times/week 6. has adequate social support to participate in all intervention and baseline/follow-up assessment sessions throughout 40 weeks. 7. has ability to read and speak English Exclusion Criteria: 1. dependent on ventilation support 2. has implanted stimulator (e.g., pacemaker, vagus nerve stimulator, cochlear implant, etc.) or baclofen pump 3. has metallic devices and implants in the head (e.g., deep brain stimulators, aneurysm clips/coils, and stents, vagus nerve stimulators) 4. has a history or current signs/symptoms of syringomyelia (progressive pain, muscle weakness, and/or sensory loss; deterioration of bowel/bladder function) 5. has autoimmune etiology of spinal cord dysfunction/injury 6. has received botulinum toxin injections in upper extremity muscles in the prior 6 months 7. has tendon transfer or nerve transfer surgery in the upper extremity, 8. taking tizanidine, dantrolene or diazepam 9. has history of seizures or increased risk for seizures 10. has history of chronic headaches or migraines 11. has history of neurologic diseases, such as stroke, multiple sclerosis, traumatic brain injury, etc. 12. has peripheral neuropathy (diabetic polyneuropathy, entrapment neuropathy, etc.) 13. has rheumatic diseases (rheumatoid arthritis, systemic lupus erythematosus, etc.) 14. has significant medical disease; including uncontrolled systemic hypertension with values above 170/100 mmHg; cardiac or pulmonary disease; uncorrected coagulation abnormalities or need for therapeutic anticoagulation 15. has cardiovascular or musculoskeletal disease or injury that would prevent full participation in physical therapy intervention 16. unhealed fracture, contracture, pressure sore, or frequent urinary tract infections or other illnesses that might interfere with upper extremity rehabilitation or testing activities 17. has a history of severe allergy (i.e., allergic reaction that could not be treated with antihistaminic medication 18. has alcohol and/or drug abuse (subject's verbal statement) 19. has cancer 20. pregnant (Childbearing potential will be asked at screening, baseline, and every subsequent visit in which the subject would receive transcutaneous spinal cord stimulation and/or Transcranial Magnetic Stimulation whether the participant could be pregnant. Pregnancy will be ruled out by an over-the-counter urine pregnancy test for all females of childbearing potential (1) at the time of enrollment, (2) prior to all sessions that include Transcranial Magnetic Stimulation, and also prior to the intervention phases of (3) closed-loop or (4) open-loop stimulation. Additional pregnancy tests may be performed if there is a concern of pregnancy.) 21. lack of ability to fully comprehend, cooperate and/or safely perform study procedures in the investigator's opinion/judgment 22. unable to read and/or comprehend the consent form
Contact & Investigator
Chet Moritz, Ph.D.
PRINCIPAL INVESTIGATOR
University of Washington
Frequently Asked Questions
Who can join the NCT05267951 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 70 Years, studying Spinal Cord Injuries. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05267951 currently recruiting?
Yes, NCT05267951 is actively recruiting participants. Contact the research team at finanici@uw.edu for enrollment information.
Where is the NCT05267951 trial being conducted?
This trial is being conducted at Seattle, United States.
Who is sponsoring the NCT05267951 clinical trial?
NCT05267951 is sponsored by University of Washington. The principal investigator is Chet Moritz, Ph.D. at University of Washington. The trial plans to enroll 9 participants.